Skip to main content

Table 2 Perioperative outcomes of the four cohorts

From: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?

Value

HCC (n = 9)

CCa (n = 4)

GBC (n = 3)

PCa (n = 1)

p value

PCI

12 [6–16]

7 [4–13]

21 [7–27]

10 [10]

0.538

Number of organs resected

2 [1–5]

2 [1–5]

4 [4–9]

6 [6]

0.626

CC score

    

0.668

 CC-0/1

7 (78)

4 (100)

1 (33)

1 (100)

 

 CC-2/3

2 (22)

0 (0)

2 (67)

0 (0)

 

EBL, cc

500 [100–700]

450 [225–750]

600 [200–2000]

150 [150]

0.780

OR time, min

305 [250–388]

304 [231–327]

345 [302–385]

358 [358]

0.795

LOS, days

5 [5–9]

6 [6–8]

7 [5–8]

3 [3]

0.833

ICU stay

4 (44)

0 (0)

1 (33)

0 (0)

0.430

Perioperative major morbidity

1 (11)

0 (0)

1 (33)

0 (0)

0.471

Perioperative mortality

1 (11)

0 (0)

0 (0)

0 (0)

0.815

Adjuvant chemotherapy

7 (78)

4 (100)

3 (100)

1 (100)

0.569

Follow-up time, months

23 [3–42]

19 [15–21]

2 [0–13]

15 [15]

0.493

  1. HCC hepatocellular carcinoma, CCa cholangiocarcinoma, GBC gallbladder cancer, PCa pancreatic cancer, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy, PCI peritoneal cancer index, CC completeness of cytoreduction, EBL estimated blood loss, OR operating room, LOS length of stay, ICU intensive care unit